Side 4Forord DHR's styregruppe praesenterer hermed årsrapporten for 2016. Der er nu i perioden 1995-2015 i alt indberettet ca. 150.000 primaere og 23.400 revisioner til DHR. DHR har laenge levet op til de gaeldende krav for indrapportering.Dette års komplethedsgrad på 97,5 % for primaere THA er meget tilfredsstillende, mens kompletheden for revisions THA er på 90,3 % og såfremt at der fratraekkes revision af hemialloplastik stiger det til 94,4%. Da standarden er 95% er det ikke tilfredsstillende. Der skal lyde en stor tak fra styregruppen til alle laeger, sekretaerer og andet personale, der yder et stort stykke arbejde for, at vores datakomplethed fra de fleste afdelinger er god. Også en stor tak til vores sekretariat, der sørger for den gode kontakt til afdelingerne. Årets rapportI denne rapport praesenteres 20 års follow-up af de første indrapporterede patienter til registeret. Antal indberetninger for såvel primaere som revisioner er nogenlunde uaendret de sidste 5 år. Nyheder i DHR-rapporten 2016Som diskuteret på DOS-kongressen 2015, er der foretaget en raekke aendringer af indikatorerne primaert mhp. at rapportere mere relevante data til de indberettende afdelinger. Derfor er der nu fokus på 30 og ikke 90 dages genindlaeggelse uanset årsag samt 2 års revisions rater, hvor alle reoperationer og eventuel lukket reponering indgår. Desuden er der indført en registrering af 5 års proteseoverlevelse. Standarder for de nye indikatorer vil blive justeret, når der er erfaringer med dem. Indtil videre er de pragmatisk sat til landsgennemsnittet. AEndringer i styregruppenFor Region Nordjylland erstattes Michael Ulrich Jensen af Mogens Berg Laursen. Michael takkes for et rigtig stort stykke arbejde specielt ifm. oprettelse af databasen for MoM. Han ønskes held og lykke med sin nye praksis i Århus. Hans Peder Graversen (repraesentant for dataansvarlig myndighed) er trådt ud af styregruppen og erstattes af kvalitetskonsulent Sofia Kyndesen, Region Hovedstaden. Hans Peder Graversen takkes for den tid, han har siddet i styregruppen. Optimering af den elektroniske indtastning af MoM patienterStyregruppen har arbejdet med at optimere den elektroniske indtastning af MoM patienterne, og aendringerne vil blive implementeret i løbet af 2016. Dette vil betyde, at indtastningen vil tage vaesentlig kortere tid end tidligere. Indrapportering skal sikre, at vi til enhver tid kan oplyse om, hvordan det går med patienter med MoM-hofter. Styregruppen er medvidende om, at der er en meget dårlig komplethed i MoM-databsen, hvilket der nu skal rådes bod på. Vi har derfor besluttet følgende løsning: Ved kontrol af en patient med en MoM-hofte udfyldes skema enten elektronisk eller i papir form:• Smerter og ion metal måling: Der indtastes de første og seneste man har noteret sig, og derefter indtastes alle nye prospektivt.• Billeddiagnostisk: Alle resultater fra undersøgelser indtastes.• Patologi: Alle resultater fra eventuelle reoperationer skal indtastes.Dette skulle gøre det mere lempeligt at få indrapporteret de patienter, der endnu ikke er...
This study was performed to investigate whether an intravenous (IV) strategy based on newgeneration midline catheters is an efficacious alternative to a conventional IV strategy consisting of peripheral venous catheters and central venous catheters, for patients needing IV therapy exceeding 5 days. Methods: This was a prospective, randomized, controlled study. Patients requiring more than 5 days of IV treatment were randomized to either a midline catheter-based IV strategy or a conventional strategy. The primary endpoint was the composite of the insertion of a central venous catheter (CVC) or the need for four or more peripheral venous catheter (PVC) insertions. The secondary outcomes included catheter dwell times and reasons for premature removal. Results: One hundred and twenty patients were included. The fraction of patients receiving four or more PVCs or having a CVC inserted was 12/58 (21%) in the midline group versus 38/58 (66%) in the conventional group (p < 0.001); the number needed to treat was 2.2. The median overall catheter dwell time was 7 days (range 0-60 days) in the midline group and 4 days (range 0-84 days) in the conventional group (p = 0.002). Conclusion:In patients requiring more than 5 days of IV therapy, a midline catheter strategy reduced the need for insertion of a CVC or four or more PVCs.
Background/Objective: Fracture risk is increased in patients with type 1 diabetes.We aimed to evaluate bone mineral density (BMD) and to identify risk factors associated to lower BMD in Danish children and adolescents with type 1 diabetes. Methods:In this cross-sectional study BMD Z-score were determined by dual-energy X-ray absorptiometry (DXA) from a cohort of otherwise healthy children and adolescents with type 1 diabetes. Puberty Tanner stage, hemoglobin A1c (HbA1c), disease duration, and age at diabetes onset were investigated for associations to DXA results. Results:We included 85 patients, 39 girls, 46 boys, with a median (range) age of 13.2 (6-17) years; disease duration 4.2 (0.4-15.9) years; HbA1c of the last year 61.8 (41-106) mmol/mol. Our patients were taller and heavier than the background population. When adjusted for increased height SD and body mass index SD, no overall difference in BMD Z-score was found. When stratified by sex, boys had significantly increased adjusted mean BMD Z-score, 0.38 (95% confidence interval [CI]: 0.13;0.62), girls; −0.27 (95% CI: −0.53;0.00). For the whole cohort, a negative correlation between mean latest year HbA1c and BMD Z-score was found, adjusted ß −0.019 (95%CI: −0.034;−0.004, P = 0.01). Poor glycemic control (HbA1c > 58 mmol/mol [7.5%]) within the latest year was likewise negatively correlated with BMD Z-score, adjusted ß −0.35 (95%CI: −0.69;−0.014, P = 0.04). Conclusions:Our study suggests that elevated blood glucose has a negative effect on the bones already before adulthood in patients with type 1 diabetes, although no signs of osteoporosis were identified by DXA. K E Y W O R D S adolescent, bone density, child, diabetes mellitusglycated hemoglobin A, type 1
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.